๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06907602Locally Advanced Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Phase 2/3
120
Beijing
2024-01-12
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou
2024-01-11
Recruiting
A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
NCT06219356Non-Hodgkin Lymphoma
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1
110
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang
2024-01-11
Recruiting
Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)
NCT06157502Ischemic Stroke, Acute
Beijing Tiantan Hospital
Phase 3
1,380
Beijing, Chongqing, Qianjiang, Guangzhou, Heyuan, Maoming, Meizhou, Yunfu
2024-01-11
Recruiting
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
NCT06155396Cervical Cancer
RemeGen Co., Ltd.
Phase 2
116
Bengbu, Beijing, Chongqing, Nanning, Changsha, Nanchang, Shenyang, Jinan
2024-01-11
Recruiting
A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy
NCT06549907MSS Metastatic Colorectal Cancers, MSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
Peking University Cancer Hospital & Institute
Observational
50
Beijing
2024-01-10
Active, closed
Toripalimab for High-risk Locally Advanced Cervical Cancer
NCT06416696Cervical Cancers
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
57
Beijing
2024-01-09
Active, closed
A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China
NCT05821855Open-angle Glaucoma, OAG
AbbVie
Phase 4
120
Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Wuhan, Qingdao, Chengdu
2024-01-09
Active, closed
Evaluate the Diagnostic Efficacy, Pharmacokinetics and Safety of 68Ga-DOTATATE Injection PET/CT in NETs
NCT07119242NETs
HTA Co., Ltd.
Phase 3
95
Beijing
2024-01-08
Recruiting
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
NCT06419413Asthma
AstraZeneca
Observational
355
Chengdu, Beijing, Changsha, Dongguan, Foshan, Guangzhou, Hainan, Hohhot
2024-01-08
Recruiting
Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
NCT06211166Acute Leukemia, MDS, MDS/MPN, CML
Peking University People's Hospital
Observational
300
Beijing
2024-01-08
Recruiting
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
NCT06192979Amyloidosis; Systemic, AL Amyloidosis
Jin Lu, MD
Not applicable
41
Beijing, Nanjing, Qingdao, Xiโ€™an
2024-01-05
Recruiting
Rivaroxaban in Idiopathic Membranous Nephropathy
NCT07404436Idiopathic Membranous Nephropathy
Beijing Friendship Hospital
Phase 4
134
Beijing
2024-01-05
Recruiting
A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors
NCT06374173Advanced or Metastatic Solid Tumors
Hefei TG ImmunoPharma Co., Ltd.
Phase 1
123
Beijing
2024-01-03
Recruiting
Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
NCT06111638Hemophilia A
Shanghai Xinzhi BioMed Co., Ltd.
Phase 2/3
55
Beijing, Guangzhou, Guiyang, Wuhan, Changsha, Suzhou, Xiโ€™an, Chengde
2024-01-03
Active, closed
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
NCT06079281Hypophosphatasia
Alexion Pharmaceuticals, Inc.
Phase 3
124
Beijing, Changsha, Chengdu, Nanchang, Qingdao, Shanghai, Shenzhen
2024-01-03
Active, closed
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
NCT06056804Locally Advanced Rectal Cancer
Beijing Friendship Hospital
Phase 2
20
Beijing
2024-01-03
By invitation
An Early Warning Model of Unfavorable Outcomes Following Endovascular Interventional Treatment of Intracranial Aneurysm
NCT06364293Intracranial Aneurysm
Beijing Tiantan Hospital
Observational
750
Beijing
2024-01-01
Recruiting
MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
NCT06748690Gastrointestinal Stromal Tumor of Stomach, Submucosal Tumor of Stomach
Peking University People's Hospital
Not applicable
96
Beijing
2024-01-01
Recruiting
The Study of Differences in Eosinophil Function and Subsets in Patients With Eosinophilic Pulmonary Diseases
NCT06944418Eosinophil Subtype, Eosinophilic Pulmonary Diseases
Peking Union Medical College Hospital
Observational
300
Beijing
2024-01-01
Recruiting
Helicobacter Pylori Infection Status and Pathological Features for Predicting Gastric Cancer Biological Behavior and Prognosis: A Real-World Observational Study
NCT07724496Helicobacter Pylori, Early Gastric Cancer
Chinese PLA General Hospital
Observational
1,500
Beijing
2024-01-01
Active, closed
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
NCT06215677Colon Cancer, Mismatch Repair Deficiency, Immunotherapy
Peking Union Medical College Hospital
Phase 2
18
Beijing
2024-01-01
Recruiting
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
NCT07037680Locally Advanced Non-Small Cell Lung Cancer, Thoracic Radiotherapy, Safety
JIANYANG WANG
Phase 2
44
Beijing
2024-01-01
Not yet open
China National Study of Adrenal Venous Sampling
NCT06192238Hyperaldosteronism
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
1,500
Beijing, Chongqing, Xiamen, Lanzhou, Foshan, Guangzhou, Shenzhen, Nanning
2024-01-01
Recruiting
Interferon-ฮฑ for TP53 Myeloid Malignancy Post Allo-HSCT
NCT06130579Myeloid Leukemia, Myelodysplastic Syndromes
Peking University People's Hospital
Phase 2
35
Beijing
2024-01-01
By invitation
Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
NCT06959784Diabetes Mellitus, Cardiovascular Diseases, Cerebrovascular Disease
China-Japan Friendship Hospital
Phase 4
142
Beijing
2024-01-01
Recruiting
A Multi-center RCT to Evaluate Subsegmental BTVA Treatment for Severe Emphysema
NCT06152107Severe Emphysema
Shanghai Chest Hospital
Not applicable
100
Zhengzhou, Beijing, Chengdu, Linyi, Nanchang, Shanghai, Shijiazhuang, Zhejiang
2024-01-01
Recruiting
Clinical Characteristics and Analysis of Pituitary Complex and Rare Diseases
NCT06435195Pituitary Diseases
Peking Union Medical College Hospital
Observational
3,000
Beijing
2024-01-01
Recruiting
A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration
NCT06564428Ovarian Neoplasms
Peking University Third Hospital
Observational
1,000
Beijing
2024-01-01
Recruiting
Adverse Cardiovascular Events During Painless Gastroscopy Diagnosis and Treatment in Elderly Frail Patients
NCT06192082Anesthesia
Beijing Friendship Hospital
Not applicable
226
Beijing
2024-01-01
Recruiting
Clinical Cohort Study of Knee Arthroplasty Assisted by Digital Technology
NCT06010979Knee Osteoarthritis
Tian Hua
Observational
12,000
Beijing
2024-01-01
By invitation
The Clinical Efficacy of Anterolateral Complex Augmentation in Patients With ACL Rupture Combined With Excessive Internal Tibial Rotation Subluxation: A Bidirectional Cohort Study
NCT06961292Anterior Cruciate Ligament Rupture
Peking University Third Hospital
Observational
335
Beijing
2024-01-01
Recruiting
Radiomics of Intra-abdominal and Subcutaneous Adipose Tissue Predict the Efficacy of Bariatric Surgery (RISABS)
NCT06169033Obesity, Type 2 Diabetes Mellitus, Bariatric Surgery
China-Japan Friendship Hospital
Observational
800
Beijing
2024-01-01
Recruiting
Glofitamab in Chinese Patients With R/R DLBCL
NCT06481826DLBCL - Diffuse Large B Cell Lymphoma
Peking Union Medical College Hospital
Observational
20
Beijing
2024-01-01
Recruiting
Clinical Trial of Acupoint Application in Improving the Sequelae of Pelvic Inflammatory Disease and Chronic Pelvic Pain
NCT06360965Pelvic Inflammatory Disease, Chronic Pelvic Pain Syndrome
Beijing Hospital of Integrated Traditional Chinese and Western Medicine
Not applicable
102
Beijing
2024-01-01
Recruiting
The Safety and Efficacy of Single Antiplatelet Therapy After Pipeline Flex with Shield for Intracranial Aneurysms
NCT06474884Treatment
Xuanwu Hospital, Beijing
Observational
165
Beijing
2024-01-01
Recruiting
Standardized Study Protocol of Percutaneous Vertebroplasty Based on Pedicle Nine-Grid Zoning Method
NCT07616583Osteoporotic Vertebral Compression Fractures, Vertebroplasty
Beijing Friendship Hospital
Not applicable
68
Beijing
2024-01-01
Recruiting
Efficacy and Safety of Photodynamic Therapy for CIN3
NCT07009327Precancerous Cervical Lesion
Peking University Third Hospital
Not applicable
100
Beijing
2024-01-01
Recruiting
Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors
NCT06454955B7H3, CD276 Affibody, PET/CT Imaing
Peking University Cancer Hospital & Institute
Phase EARLY_PHASE1
50
Beijing
2024-01-01
Recruiting
MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors
NCT06170294Advanced Solid Tumor
Peking University
Phase 1
20
Beijing
2024-01-01
Recruiting
B7-H3 NIR Imaging for Osteosarcoma Surgery
NCT06778603Osteosarcoma, Resection Margins, B7-H3 Probe, Local Recurrence
Peking University People's Hospital
Phase 1/2
32
Beijing
2024-01-01
Recruiting
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
NCT06360042Unresectable Hepatocellular Carcinoma
Peking University Cancer Hospital & Institute
Phase 2
111
Beijing
2024-01-01
Recruiting
Establishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale
NCT06953622Migraine, Patent Foramen Ovale
Peking University Third Hospital
Observational
330
Beijing
2024-01-01
Recruiting
Microfracture With Platelet Rich Plasma Gel Injection for Osteochondral Lesion of the Talus
NCT06358807Osteochondral Lesion of Talus, Microfractures, Platelet Rich Plasma
Peking University Third Hospital
Not applicable
70
Beijing
2024-01-01
Recruiting
The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics
NCT06362343Pulmonary Embolism
Peking Union Medical College Hospital
Observational
300
Beijing
2024-01-01
Recruiting
Cerebral Microembolization Associated With PFO Closure
NCT06347276Thrombosis Cardiac, Atrial Septal Defect, Patent Foramen Ovale (PFO)
China National Center for Cardiovascular Diseases
Observational
800
Beijing
2024-01-01
Recruiting
Prospective Validation and Application of an Artificial Intelligence-based Model for Evaluating the Efficacy of Breast Cancer Patients After Neoadjuvant Therapy
NCT06649565Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
300
Beijing
2024-01-01
Recruiting
Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC
NCT06345287Head and Neck Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
133
Beijing
2024-01-01
Recruiting
Establishment and Promotion of an AI-Based Early Warning System for Prostate and Bladder Cancer Screening in the Male Community Population of Beijing
NCT07319923Prostate Cancer, Community-based Screening
Peking University First Hospital
Observational
3,000
Beijing
2024-01-01
Recruiting
Haplo-HSCT for Myelofibrosis
NCT06674382Myelofibrosis
Peking University People's Hospital
Not applicable
39
Beijing
2024-01-01
Recruiting
PEEP Titration and Lung Recruitment Potential Assessed by 3D EIT
NCT06594601ARDS, Respiratory Failure
Peking Union Medical College Hospital
Observational
50
Beijing
2024-01-01
Not yet open
Modified Laparoscopic Transcystic Biliary Drainage in the Management of Cholecystocholedocholithiasis
NCT06011941Common Bile Duct Calculi, Acute; Cholecystitis, Choledocholithiasis, Acute Cholecystitis With Obstruction, Acute Cholangitis
Peking University Third Hospital
Not applicable
310
Beijing
2024-01-01
Recruiting
Photoacoustic/Ultrasound Imaging in Patients of Dermatomyositis With Calcinosis Cutis: Characteristic Findings and Treatment Response Evaluation
NCT07037472Dermatomyositis, Dermatomyositis With Calcinosis Cutis
Peking Union Medical College Hospital
Not applicable
100
Beijing
2024-01-01
Recruiting
Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis (TARIC-1)
NCT06178419Cerebral Ischemia, Takayasu Arteritis
Xuanwu Hospital, Beijing
Not applicable
44
Beijing
2024-01-01
By invitation
Treatable Traits of Severe Asthma
NCT06811740Asthma
Beijing Chao Yang Hospital
Not applicable
160
Beijing
2024-01-01
By invitation
Hypofractionated Radiotherapy for HNSCC in Elderly Patients
NCT06768125Head and Neck Cancer Squamous Cell Carcinoma, ELDERLY PEOPLE, Hypofractionation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
51
Beijing
2024-01-01
Recruiting
AI Detection of Bladder Tumors Under Endoscopy
NCT06474338Bladder Tumor
Peking Union Medical College Hospital
Observational
1,000
Beijing
2024-01-01
Recruiting
LivQ-boxยฎ Parameters in the Diagnosis of Liver Inflammation
NCT06802731Liver Inflammation, Fatty Liver Disease
Wuxi Hisky Medical Technology Co Ltd
Observational
365
Beijing
2024-01-01
Recruiting
Bariatric Surgery Combined With GLP-1 Receptor Agonists Study
NCT07336862Obesity
China-Japan Friendship Hospital
Phase 1/2
200
Beijing
2024-01-01
Recruiting
The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy
NCT06843304Diabetic Nephropathy, T2DM
Chinese PLA General Hospital
Observational
2,000
Beijing
2024-01-01
Recruiting
The Development and Validation of MRI-AI-based Predictive Models for csPCa
NCT06842264Prostate Cancer
Peking University First Hospital
Observational
3,000
Beijing
2024-01-01
Recruiting
The Effects of Immunonutrition Therapy on Locally Advanced Cervical Cancer Patients
NCT06349148Cervical Cancers
SHUANG ZHENG JIA, PhD
Not applicable
50
Beijing
2024-01-01
Not yet open
Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)
NCT06198907Non-Small-Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
69
Beijing
2024-01
Not yet open
Effects and Safety of Clonidine Patch on Young and Middle-aged Smokers With Mild Hypertension
NCT05416840Hypertension
Jing Liu
Phase 4
92
Beijing
2024-01
Recruiting
A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
NCT06211647Advanced Solid Tumor
Ruimin Wang
Phase 1
20
Beijing
2024-01
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624Prostate Cancer Metastatic
Merck Sharp & Dohme LLC
Phase 3
1,310
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha
2023-12-31
Active, closed
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879Essential Thrombocythemia
Merck Sharp & Dohme LLC
Phase 3
340
Bengbu, Hefei, Beijing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou
2023-12-31
Recruiting
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
NCT06180174B Cell Lymphoma, Non Hodgkin Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1
24
Beijing
2023-12-31
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945Breast Cancer
Daiichi Sankyo
Phase 3
250
Beijing, Fujian, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang
2023-12-30
Recruiting
Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism
NCT06773663Primary Aldosteronism, Primary Aldosteronism Due to Aldosterone Producing Adenoma
Peking Union Medical College Hospital
Phase 1/2
150
Beijing
2023-12-30
Recruiting
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
NCT06189495Systemic Sclerosis Associated Interstitial Lung Disease, Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD), Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
30
Beijing, Wuhan, Jinan, Chengdu
2023-12-30
Recruiting
Off-the-shelf CD123 CAR-NK for R/R AML
NCT06201247Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Peking University People's Hospital
Phase EARLY_PHASE1
12
Beijing
2023-12-30
Recruiting
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb
Phase 1/2
460
Beijing, Guangzhou, Zhengzhou, Suzhou, Nanchang, Shenyang, Shanghai, Hangzhou
2023-12-29
Recruiting
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
NCT06170489Hodgkin Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
185
Beijing
2023-12-28
Recruiting
a PROspective Case Control Study to Develop and Validate a Blood Test FOr mUlti-caNcers Early Detection๏ผˆPROFOUND๏ผ‰
NCT06217900Cancer
Shanghai Weihe Medical Laboratory Co., Ltd.
Observational
16,666
Beijing, Changchun, Guangzhou, Hangzhou, Shenyang
2023-12-28
Not yet open
Relmacabtagene Autoleucel in Hematologic Malignancies
NCT06142188Lymphoma, B-Cell, Large B-cell Lymphoma, Follicular Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Observational
150
Beijing
2023-12-28
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
Sanofi
Phase 3
943
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Jiazhuang
2023-12-27
Recruiting
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
NCT06235229Multiple Myeloma
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
110
Beijing, Hangzhou, Jinan, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an
2023-12-26
By invitation
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
NCT06616727Recurrent Glioblastoma Multiforme (GBM)
Shanghai Simnova Biotechnology Co.,Ltd.
Phase 1
50
Beijing
2023-12-26
Recruiting
A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B
NCT06263959Chronic Hepatitis B
Fujian Akeylink Biotechnology Co., Ltd.
Phase 2
45
Beijing
2023-12-26
Recruiting
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
NCT06155084Metastatic Castration-resistant Prostate Cancer
Hinova Pharmaceuticals Inc.
Phase 1/2
84
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Zhengzhou
2023-12-26
Active, closed
Study of Human Bone Marrow Mesenchymal Stem Cells in APAP
NCT06111846Autoimmune Pulmonary Alveolar Proteinosis
Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Phase 2
10
Beijing
2023-12-25
Recruiting
A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis
NCT06406205Lupus Nephritis
Qilu Pharmaceutical Co., Ltd.
Phase 3
270
Bengbu, Bozhou, Hefei, Beijing, Fuzhou, Dalian, Shanghai, Changzhi
2023-12-25
Recruiting
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
NCT06177041Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 3
486
Beijing
2023-12-25
Recruiting
Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
NCT06139575Prostate Cancer
Bivision Pharmaceuticals, Inc.
Phase 1/2
90
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Wuxi
2023-12-22
Active, closed
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis๏ผšContezolid, Delamanid and Bedaquiline Cohort
NCT06081361Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
Beijing Chest Hospital
Phase 3
186
Beijing, Changsha, Hefei, Jiamusi, Shandong, Xi'an, Xinxiang, Shijiazhuang
2023-12-22
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,264
Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou
2023-12-21
Recruiting
PrevaLence of Albuminuria in Patients With CARdiovascular Disease and Type 2 Diabetes Mellitus in China: a National Cross-sectional Study
NCT06336239Cardiovascular Disease, Type 2 Diabetes Mellitus
Beijing Anzhen Hospital
Observational
3,000
Beijing, Chongqing, Haidong, Guangzhou, Shijiazhuang, Luoyang, Yongcheng, Zhengzhou
2023-12-21
Active, closed
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naรฏve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
NCT06140836Carcinoma, Non-Small-Cell Lung
Bristol-Myers Squibb
Phase 3
190
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-12-21
Recruiting
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157Neoplasms
Janssen Research & Development, LLC
Phase 1
300
Beijing, Tianjin
2023-12-20
Active, closed
Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs
NCT06175637Neurofibroma, Plexiform
AstraZeneca
Observational
409
Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang
2023-12-20
Recruiting
Efficacy and Safety of Sirolimus-Coated Spiral Balloon for Coronary Bifurcation Lesions
NCT06618248Coronary Bifurcation Lesion
Dongguan TT Medical
Not applicable
280
Beijing
2023-12-20
Recruiting
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566CLL/SLL
Ascentage Pharma Group Inc.
Phase 3
400
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Nanning, Zhengzhou, Wuhan
2023-12-20
Recruiting
Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
NCT06167694Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2
146
Beijing, Guangzhou
2023-12-20
Not yet open
CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
NCT06183736Advanced Solid Tumors
Convalife (Shanghai) Co., Ltd.
Phase 2
98
Beijing
2023-12-20
Recruiting
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
NCT06082102Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
324
Bengbu, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Dalian
2023-12-19
Active, closed
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411Vitiligo
AbbVie
Phase 3
614
Beijing, Guangzhou, Wuhan, Xi'an, Jinan, Shanghai, Chengdu, Tianjin
2023-12-19
Recruiting
DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
NCT06190665Hepatocellular Carcinoma
Zhongda Hospital
Not applicable
188
Beijing, Nanjing
2023-12-19
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,314
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Changsha, Nanjing
2023-12-18
Recruiting
VR Interventions to Reduce the Prevalence of Delirium in ICU Patients
NCT05525702Delirium
Peking Union Medical College Hospital
Not applicable
102
Beijing
2023-12-18
Rows per page Showing 3801–3900 of 5484
Previous 37 38 39 40 41 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=39

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.